Merck sees pivotal victory for $3B eye disease prospect
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Merck sees pivotal victory for $3B eye disease prospect" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include firstwordpharma.com, Ophthalmology Times, Business Wire and Endpoints News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 43d ago.
Quick answers
Why is "Merck sees pivotal victory for $3B eye disease prospect" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Merck & Co.'s Wnt drug wins in ophthalmology study, but safety concerns crop up firstwordpharma.com · 45d ago
- Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial | Eye Care Network Ophthalmology Times · 45d ago
- Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema Business Wire · 45d ago
- Merck’s return to ophthalmology snags first success Endpoints News · 45d ago
- Merck's drug for diabetes-related eye disease meets trial goal Reuters · 45d ago
- Merck sees pivotal victory for $3B eye disease prospect Fierce Biotech · 45d ago
Topics
Related trends
‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
First personalised cancer vaccine cuts risk of disease returning in major trial
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
Exclusive | She was ready to die. Now she’s in remission
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.